Literature DB >> 17591567

Low-grade non-hodgkin lymphomas.

Richard W Tsang1, Mary K Gospodarowicz.   

Abstract

The most common low-grade non-Hodgkin lymphomas are of B-cell origin. This review will focus on follicular lymphomas and extranodal marginal zone lymphomas, also known as mucosa-associated lymphoid tissue (MALT) lymphomas. These are radiation-sensitive lymphomas. Moderate doses (30-35 Gy) for these stage I and II low-grade lymphomas result in long-term local control and possible cure. Involved-field radiation therapy is the standard approach and produces minimal morbidity. However, a significant proportion of patients relapse with systemic disease outside of radiation fields. For follicular lymphoma, this occurs in approximately 50% of patients after 15 years and for nongastric MALT lymphoma 30% to 40% after 10 years. Patients with relapsed disease are not curable with chemotherapy, but the disease often remains indolent and prolonged survival is observed. For gastric MALT lymphomas associated with Helicobacter pylori but which did not respond to antibiotic therapy, radiation treatment is indicated and almost always curative. For localized MALT lymphomas not related to microorganisms, radiation therapy is the initial standard therapy regardless of anatomic location. Patients with stage III and IV low-grade lymphoma and local symptoms are often successfully palliated with a low dose regimen of 2 x 2 Gy (total dose 4 Gy).

Entities:  

Mesh:

Year:  2007        PMID: 17591567     DOI: 10.1016/j.semradonc.2007.02.006

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  7 in total

Review 1.  Nodal follicular lymphoma: the role of radiotherapy for stages I and II.

Authors:  Frank Heinzelmann; Marianne Engelhard; Hellmut Ottinger; Michael Bamberg; Martin Weinmann
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

2.  Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.

Authors:  Soley Bayraktar; Ulas D Bayraktar; Alexandra Stefanovic; Izidore S Lossos
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

3.  Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study.

Authors:  Alfred Haidenberger; Sabine Fromm-Haidenberger; Alexander de Vries; Bela-Andre Popper; Michael Steurer; Ira Skvortsova; Johanna Kantner; Eberhard Gunsilius; Peter Lukas
Journal:  Strahlenther Onkol       Date:  2011-04-26       Impact factor: 3.621

4.  Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin.

Authors:  Olga K Weinberg; Lisa Ma; Katie Seo; Andrew H Beck; Reetesh K Pai; Anjali Morales; Youn Kim; Uma Sundram; Daryl Tan; Sandra J Horning; Richard T Hoppe; Yasodha Natkunam; Daniel A Arber
Journal:  Am J Surg Pathol       Date:  2009-04       Impact factor: 6.394

Review 5.  How we treat mature B-cell neoplasms (indolent B-cell lymphomas).

Authors:  Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe
Journal:  J Hematol Oncol       Date:  2021-01-06       Impact factor: 17.388

6.  Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone.

Authors:  Naseer Ahmed; Timothy E Owen; Morel Rubinger; Gaynor Williams; Zoann Nugent; Shahida Ahmed; Andrew Cooke
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

Review 7.  Radiotherapy of follicular lymphoma: updated role and new rules.

Authors:  Joachim Yahalom
Journal:  Curr Treat Options Oncol       Date:  2014-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.